Aicar como fármaco promissor no tratamento e controle do diabetes Mellitus tipo 2: uma revisão sistemática

Abstract

Introduction: O 5-aminoimidazole-4-carboxamide ribofuranoside, known as AICAR, is a synthetic analog of AMPK hat stimulates metabolism to be more oxidative, showing beneficial effects similar to physical exercise without performing them. This medicine appears to be promising for treatment of chronic metabolic diseases like type 2 diabetes mellitus. Objectives: Analyze and contextualize key findings related to the treatment of type 2 diabetes mellitus with the use of AICAR. Methods: Systematic review of bibliographic studies, in english, PubMed and Science Direct electronic databases, published between 2008 and 2019, using the descriptors AICAR and Diabetes and AICAR and Insulin. Results and Discussion: AICAR has effects that cause inhibition of hepatic glucose production and stimulate insulin-independent glucose uptake. It also has effects that lower plasma glucose concentrations, in addition to suppressing lipolysis resulting in a decline in plasma NEFA concentration. AICAR also improves insulin sensitivity in skeletal muscles and shows decreased production of inflammatory cytokines causing increased insulin resistance. All of these effects are demonstrated in studies presented without physical exercise. Conclusion: This study identifies that AICAR is a potential drug for the treatment of type 2 diabetes mellitus as it has several beneficial effects, metabolic and physiological factors important to the body.